PT2725028T - Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk - Google Patents

Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk

Info

Publication number
PT2725028T
PT2725028T PT131978157T PT13197815T PT2725028T PT 2725028 T PT2725028 T PT 2725028T PT 131978157 T PT131978157 T PT 131978157T PT 13197815 T PT13197815 T PT 13197815T PT 2725028 T PT2725028 T PT 2725028T
Authority
PT
Portugal
Prior art keywords
intermediates
synthesis
kinase inhibitors
pyrimidine compounds
substituted pyrazolo
Prior art date
Application number
PT131978157T
Other languages
English (en)
Portuguese (pt)
Inventor
Haas Julia
W Andrews Steven
Jiang Yutong
Zhang Gan
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41328903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2725028(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of PT2725028T publication Critical patent/PT2725028T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/02—Ergot alkaloids of the cyclic peptide type
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
PT131978157T 2008-10-22 2009-10-21 Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk PT2725028T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10761608P 2008-10-22 2008-10-22

Publications (1)

Publication Number Publication Date
PT2725028T true PT2725028T (pt) 2016-08-31

Family

ID=41328903

Family Applications (4)

Application Number Title Priority Date Filing Date
PT131978157T PT2725028T (pt) 2008-10-22 2009-10-21 Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk
PT181512336T PT3372605T (pt) 2008-10-22 2009-10-21 Compostos de pirazolo[1,5-a]pirimidina substituídos como inibidores de quinase trk
PT97402457T PT2350071E (pt) 2008-10-22 2009-10-21 Compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da cinase trk
PT161664610T PT3106463T (pt) 2008-10-22 2009-10-21 Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT181512336T PT3372605T (pt) 2008-10-22 2009-10-21 Compostos de pirazolo[1,5-a]pirimidina substituídos como inibidores de quinase trk
PT97402457T PT2350071E (pt) 2008-10-22 2009-10-21 Compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da cinase trk
PT161664610T PT3106463T (pt) 2008-10-22 2009-10-21 Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk

Country Status (38)

Country Link
US (11) US8513263B2 (enExample)
EP (4) EP2350071B1 (enExample)
JP (5) JP5600111B2 (enExample)
KR (5) KR101853026B1 (enExample)
CN (2) CN102264736B (enExample)
AR (2) AR074052A1 (enExample)
AU (1) AU2009308465B2 (enExample)
BR (1) BRPI0919873B8 (enExample)
CA (1) CA2741313C (enExample)
CL (1) CL2011000880A1 (enExample)
CO (1) CO6440551A2 (enExample)
CR (1) CR20110261A (enExample)
CY (4) CY1118199T1 (enExample)
DK (4) DK3106463T6 (enExample)
ES (4) ES2456346T3 (enExample)
HR (3) HRP20211722T1 (enExample)
HU (4) HUE037716T2 (enExample)
IL (3) IL212341A0 (enExample)
LT (4) LT3106463T (enExample)
LU (1) LUC00150I2 (enExample)
ME (1) ME03010B (enExample)
MX (1) MX2011004204A (enExample)
MY (1) MY169791A (enExample)
NL (1) NL301033I2 (enExample)
NO (2) NO3106463T3 (enExample)
NZ (1) NZ592809A (enExample)
PL (4) PL3106463T6 (enExample)
PT (4) PT2725028T (enExample)
RS (3) RS53247B (enExample)
RU (1) RU2018131134A (enExample)
SG (3) SG196855A1 (enExample)
SI (4) SI3372605T1 (enExample)
SM (2) SMT201800244T1 (enExample)
TR (1) TR201807039T4 (enExample)
TW (4) TWI577680B (enExample)
UA (1) UA106054C2 (enExample)
UY (1) UY32192A (enExample)
WO (1) WO2010048314A1 (enExample)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2464461T3 (es) 2008-09-22 2014-06-02 Array Biopharma, Inc. Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa
SG196855A1 (en) 2008-10-22 2014-02-13 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
AU2011256380C1 (en) * 2010-05-20 2016-09-08 Array Biopharma Inc. Macrocyclic compounds as Trk kinase inhibitors
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
SG192795A1 (en) * 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as trk inhibitors
HRP20161786T1 (hr) * 2011-05-13 2017-03-10 Array Biopharma, Inc. Pirolidinil urea, pirolidinil tiourea i pirolidinil gvanidin spojevi kao inhibitori trka kinaze
CA2858958C (en) 2011-12-12 2016-10-04 Dr. Reddy's Laboratories Ltd. Substituted pyrazolo[1,5-a]pyridine as tropomyosin receptor kinase (trk) inhibitors
RU2014140735A (ru) * 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
UA117573C2 (uk) 2012-11-13 2018-08-27 Ерей Біофарма Інк. Біциклічні сполуки сечовини, тіосечовини, гуанідину й ціаногуанідину, придатні для лікування болю
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
UA116455C2 (uk) 2012-11-13 2018-03-26 Еррей Біофарма Інк. Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078328A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
HUE050215T2 (hu) 2013-01-15 2020-11-30 Incyte Holdings Corp Pim kináz inhibitorokként hasznos tiazolkarboxamid és piridinkarboxamid vegyületek
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
PL3097107T3 (pl) 2014-01-24 2020-01-31 Turning Point Therapeutics, Inc. Diarylowe związki makrocykliczne jako modulatory kinaz białkowych
ES2945905T3 (es) * 2014-02-07 2023-07-10 Exithera Pharmaceuticals Inc Compuestos y composiciones terapéuticos
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CN109970614B (zh) 2014-05-15 2023-01-13 阵列生物制药公司 作为trka激酶抑制剂的化合物及其用途
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
EP3699181B1 (en) * 2014-11-16 2023-03-01 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
CA2969540C (en) 2014-12-02 2023-03-21 Ignyta, Inc. Combinations for the treatment of neuroblastoma
EP4420732A3 (en) 2014-12-15 2024-11-27 CMG Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors
US10329294B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of IRAK4 activity
EP3268367B8 (en) * 2015-03-12 2022-11-16 Merck Sharp & Dohme LLC Carboxamide inhibitors of irak4 activity
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
CN107849113B (zh) * 2015-05-29 2022-03-22 亚尼塔公司 用于治疗具有rtk突变细胞的患者的组合物和方法
AU2016270803A1 (en) 2015-06-01 2018-01-04 Loxo Oncology, Inc. Methods of diagnosing and treating cancer
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
HRP20240780T1 (hr) 2015-07-06 2024-09-13 Turning Point Therapeutics, Inc. Polimorf diaril makrocikla
JP6816100B2 (ja) 2015-07-16 2021-01-20 アレイ バイオファーマ、インコーポレイテッド ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物
KR102772574B1 (ko) 2015-07-21 2025-02-24 터닝 포인트 테라퓨틱스, 인크. 키랄 디아릴 매크로사이클 및 이것의 용도
CA2995997A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10724102B2 (en) 2015-10-26 2020-07-28 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
KR20180081790A (ko) 2015-11-19 2018-07-17 블루프린트 메디신즈 코포레이션 Ntrk 관련 장애의 치료에 유용한 화합물 및 조성물
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
PL3439663T3 (pl) 2016-04-04 2024-11-18 Loxo Oncology, Inc. Sposoby leczenia nowotworów wieku dziecięcego
SG11201808559PA (en) 2016-04-04 2018-10-30 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
FI3800189T3 (fi) * 2016-05-18 2023-07-31 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin valmistaminen
RU2019105587A (ru) 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN108003161B (zh) * 2016-10-28 2020-10-09 正大天晴药业集团股份有限公司 神经营养因子酪氨酸激酶受体抑制剂
AU2017348826B2 (en) * 2016-10-28 2021-12-02 Centaurus Biopharma Co., Ltd. Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
ES2948194T3 (es) 2017-01-18 2023-09-01 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
KR102718538B1 (ko) 2017-07-19 2024-10-21 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
JP7224334B2 (ja) 2017-07-28 2023-02-17 ターニング・ポイント・セラピューティクス・インコーポレイテッド 大環式化合物およびその使用
FI3661935T3 (fi) * 2017-08-11 2023-01-13 Kinaasin estäjinä käyttökelpoiset pyratsolipyrimidiinit
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
AU2018320021C1 (en) 2017-08-23 2023-02-23 Centaurus Biopharma Co., Ltd. Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof
CN107556226B (zh) * 2017-09-21 2020-06-30 苏州明锐医药科技有限公司 一种拉曲替尼中间体的制备方法
CN107445879B (zh) * 2017-09-21 2020-07-24 苏州立新制药有限公司 拉曲替尼中间体的制备方法
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
HRP20251226T1 (hr) 2017-10-31 2025-12-05 Assia Chemical Industries Ltd. Soli i oblici larotrectiniba u čvrstom stanju
CA3081790C (en) 2017-11-10 2023-03-07 Angex Pharmaceutical, Inc. Macrocyclic compounds as trk kinase inhibitors and uses thereof
CN107987082B (zh) * 2017-11-14 2019-09-20 苏州东南药业股份有限公司 一种Larotrectinib的制备方法及其中间体
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7321183B2 (ja) 2017-12-15 2023-08-04 ピラミッド バイオサイエンシズ インコーポレイテッド がんを治療するためのｔｒｋキナーゼ阻害物質としての、５－（２－（２，５－ジフルオロフェニル）ピロリジン－１－イル）－３－（１ｈ－ピラゾール－１－イル）ピラゾロ［１，５－ａ］ピリミジン誘導体及び関連する化合物
SI3728271T1 (sl) 2017-12-19 2023-01-31 Turning Point Therapeutics, Inc. Makrociklične spojine za zdravljenje bolezni
CN111362949B (zh) * 2017-12-22 2021-12-21 深圳市塔吉瑞生物医药有限公司 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111848622A (zh) 2018-01-23 2020-10-30 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
TW201932472A (zh) * 2018-01-30 2019-08-16 大陸商上海吉倍生物技術有限公司 具有大環分子結構的化合物及其用途
BR112020018444A2 (pt) * 2018-03-14 2020-12-29 Fochon Pharmaceuticals, Ltd. Compostos de (2-azabiciclo[3,1,0]hexan-2-il)pirazolo[1,5-a]pirimidina substituída e imidazo[1,2-b]piridazina como inibidores de trk cinases
CN110305138B (zh) * 2018-03-27 2021-04-23 海创药业股份有限公司 一种治疗癌症的化合物及其用途
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
KR102602383B1 (ko) 2018-03-30 2023-11-14 스미도모쥬기가이고교 가부시키가이샤 건설기계의 운전지원시스템, 건설기계
WO2019206069A1 (zh) 2018-04-25 2019-10-31 北京普祺医药科技有限公司 一种二芳基巨环化合物、药物组合物以及其用途
CN110294761B (zh) * 2018-06-08 2020-09-08 南京雷正医药科技有限公司 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
CN110627812B (zh) * 2018-06-25 2022-10-11 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
CA3224985A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
EP3837241A4 (en) 2018-08-14 2022-05-18 Osteoqc Inc. FLUOROUS SS CARBOLINE COMPOUNDS
AU2019321434B2 (en) 2018-08-14 2025-05-08 Ossifi Therapeutics Llc Pyrrolo - dipyridine compounds
CN110857304B (zh) * 2018-08-24 2021-05-18 北京富龙康泰生物技术有限公司 Trk抑制剂、其制备方法和用途
CN112739691B (zh) 2018-09-03 2023-05-23 泰励生物科技（上海）有限公司 用作抗癌药的trk抑制剂
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
US20210403485A1 (en) * 2018-09-29 2021-12-30 Shandong Luye Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivative as selective trk inhibitor
CN111039947A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类蛋白受体激酶抑制剂的制备和应用
CN111171020A (zh) 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
CN111171019A (zh) 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
CN109232582B (zh) * 2018-11-28 2021-02-05 安礼特（上海）医药科技有限公司 拉洛替尼硫酸氢盐晶型及其制备和应用
CN111269233A (zh) * 2018-12-05 2020-06-12 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
CN109608464B (zh) 2018-12-12 2021-09-24 上海健康医学院 一种放射性碘标记Larotrectinib化合物及其制备方法和应用
CN109705124B (zh) * 2018-12-14 2021-09-24 上海健康医学院 一种放射性氟标记Larotrectinib化合物及其制备方法
CN113490666A (zh) 2018-12-19 2021-10-08 奥瑞生物药品公司 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
CN111362946A (zh) * 2018-12-25 2020-07-03 上海度德医药科技有限公司 一种药物化合物及其组合物和应用
CN109942574B (zh) * 2019-01-11 2022-04-01 成都阿奇生物医药科技有限公司 天奇替尼及其制备方法和用途
CN109942582B (zh) * 2019-03-15 2020-12-01 上海健康医学院 一种靶向原肌球蛋白激酶trk融合蛋白的pet探针及其合成与应用
US20220177477A1 (en) 2019-03-19 2022-06-09 Central China Normal University Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN111848626B (zh) * 2019-04-30 2021-11-30 江苏柯菲平医药股份有限公司 Trk激酶抑制剂及其用途
AU2020270303B2 (en) 2019-05-08 2023-09-07 Tyk Medicines, Inc. Compound used as kinase inhibitor and application thereof
US20200398978A1 (en) * 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
CA3145641A1 (en) * 2019-08-08 2021-02-11 Didier Rognan Trkb positive allosteric modulators
CN110804059B (zh) * 2019-09-30 2024-03-12 郑州泰基鸿诺医药股份有限公司 氨基甲酸酯类化合物、药物组合物及其应用
CN110643672A (zh) * 2019-10-15 2020-01-03 西安交通大学 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CN112812118A (zh) * 2019-11-18 2021-05-18 上海轶诺药业有限公司 一类蛋白受体激酶抑制剂的制备和应用
CN111138437B (zh) * 2019-12-04 2021-03-05 杭州华东医药集团新药研究院有限公司 取代的吡唑并[1,5-a]嘧啶氨基酸衍生物及其用途
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021187878A1 (ko) * 2020-03-17 2021-09-23 제이투에이치바이오텍 주식회사 변이성 trk 융합 단백질 억제용 화합물, 이의 의약 용도 및 제조 방법
CN113563343B (zh) * 2020-07-27 2022-05-24 杭州邦顺制药有限公司 取代的吡唑并[1,5-a]嘧啶化合物及其用途
CN114276352A (zh) * 2020-10-13 2022-04-05 上海健康医学院 一种碳-11标记Larotrectinib化合物及其制备方法
WO2022168115A1 (en) 2021-02-05 2022-08-11 Mylan Laboratories Limited A process for the preparation of larotrectinib or its salts
IT202100003887A1 (it) 2021-02-19 2022-08-19 Olon Spa Procedimento per la preparazione di larotrectinib ad elevato grado di purezza
WO2023083357A1 (zh) * 2021-11-15 2023-05-19 石药集团中奇制药技术（石家庄）有限公司 氮杂稠环酰胺类化合物的盐、其结晶形式及其用途
CN116162089B (zh) * 2022-03-23 2023-10-31 南京知和医药科技有限公司 嘧啶基抗病毒化合物的制备与使用方法
CN114907315B (zh) * 2022-05-17 2023-09-12 重庆医科大学 Selitrectinib中间体的合成方法
CN117343064B (zh) * 2022-07-05 2024-04-16 南京知和医药科技有限公司 一种具有抗病毒作用的嘧啶衍生物的制备与应用
WO2024023836A1 (en) 2022-07-27 2024-02-01 Mylan Laboratories Limited Polymorphic form of larotrectinib sulfate
WO2024051631A1 (zh) 2022-09-07 2024-03-14 苏州朗睿生物医药有限公司 一种大环咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
EP4382529A1 (en) 2022-12-07 2024-06-12 Bayer Consumer Care AG A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride
KR20240168242A (ko) * 2023-05-22 2024-11-29 주식회사 셀러스 신규한 cdk7 억제 화합물 및 이의 용도
WO2025014639A2 (en) * 2023-07-07 2025-01-16 The Johns Hopkins University Neutral sphingomyelinase inhibitors

Family Cites Families (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017286A (en) 1909-03-01 1912-02-13 Du Pont Powder Co Apparatus for treating explosive powder.
US1001160A (en) 1910-04-05 1911-08-22 Paul A Otto Aerodrome.
US1004709A (en) 1910-05-20 1911-10-03 Albert E Yerkes Spraying device.
US1013712A (en) 1911-06-03 1912-01-02 Alfred D Williams Tie and rail-fastener.
NZ234143A (en) 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
GB9212308D0 (en) 1992-06-10 1992-07-22 Ici Plc Therapeutic compositions
RU2139281C1 (ru) 1993-11-30 1999-10-10 Джи Ди Сирл энд Компани Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5430021A (en) 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
CA2206201A1 (en) 1996-05-29 1997-11-29 Yoshiaki Isobe Pyrazole derivatives and their pharmaceutical use
JPH1020683A (ja) 1996-07-05 1998-01-23 Fuji Xerox Co Ltd 画像形成装置
JP3898296B2 (ja) * 1996-08-28 2007-03-28 ポーラ化成工業株式会社 ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬
DE69827786T2 (de) 1997-04-25 2005-11-24 Takeda Pharmaceutical Co. Ltd. Condensierte pyridazine derivate,deren herstellung und verwendung
NZ511995A (en) 1999-01-21 2003-11-28 Bristol Myers Squibb Co A ras-farnesyltransferase inhibitor complex that is stable and water soluble and useful as an anti-tumour agent
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6534085B1 (en) 1999-09-23 2003-03-18 Bioresponse L.L.C. Phytochemicals for promoting weight loss
ATE446366T1 (de) 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc
GB0028575D0 (en) 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
MXPA03005648A (es) 2000-12-22 2003-10-06 Astrazeneca Ab Derivados de carbazol y su uso, como ligandos de receptor del neuropeptido y5.
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
CN101653604A (zh) 2001-05-30 2010-02-24 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
CN100343255C (zh) * 2002-04-23 2007-10-17 盐野义制药株式会社 吡唑并[1,5－a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂
US7449488B2 (en) * 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
JP4024624B2 (ja) 2002-08-26 2007-12-19 富士通株式会社 半導体装置の製造方法及び製造装置
CA2497440C (en) 2002-09-04 2011-03-22 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AU2003298942A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
GB0303910D0 (en) * 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
WO2004082458A2 (en) 2003-02-21 2004-09-30 The Johns Hopkins University Tyrosine kinome
JP2004277337A (ja) 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
EP1619203A1 (en) 2003-04-28 2006-01-25 Galpharma Co., Ltd. Galectin 9-inducing factor
PA8603801A1 (es) 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EA009517B1 (ru) 2003-06-27 2008-02-28 Байер Кропсайенс Аг Пиразолопиримидины
RS20100555A (sr) 2003-07-15 2011-08-31 Amgen Inc. Humana anti-ngf neutrališuća antitela kao selektivni inhibitori ngf signalnog puta
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US7799772B2 (en) 2003-12-18 2010-09-21 Janssen Pharmaceutica N.V. Pyrido-and pyrimidopyrimidine derivatives as anti-profilerative agents
WO2005099363A2 (en) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
CN1938311A (zh) 2004-03-30 2007-03-28 因特蒙公司 作为病毒复制抑制剂的大环化合物
JO3088B1 (ar) 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
ES2347172T3 (es) 2005-02-16 2010-10-26 Astrazeneca Ab Compuestos quimicos.
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
US7612067B2 (en) 2005-03-21 2009-11-03 Eli Lilly And Company Imidazopyridazine compounds
US20090005396A1 (en) * 2005-04-27 2009-01-01 Astrazeneca Ab Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain
EP1899323A2 (en) 2005-05-16 2008-03-19 AstraZeneca AB Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
CN100406650C (zh) 2005-06-05 2008-07-30 徐斌 一种抗特大变位的模块式梳型桥梁伸缩缝装置
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US20070025540A1 (en) 2005-07-07 2007-02-01 Roger Travis Call center routing based on talkativeness
BRPI0613962A2 (pt) 2005-07-25 2009-03-24 Intermune Inc inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
WO2007019058A1 (en) 2005-08-03 2007-02-15 Eastman Chemical Company Tocopheryl polyethylene glycol succinate powder and process for preparing same
US20070191306A1 (en) 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
WO2007024680A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
JP5366548B2 (ja) 2005-08-25 2013-12-11 クレアビリス・セラピューティクス・エスピーエー Ｋ‐２５２ａおよびその誘導体のポリマー結合体
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007044407A2 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolo (1 , 5a) pyrimidines as protein kinase inhibitors
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
DK1999129T3 (da) 2005-10-11 2011-02-07 Intermune Inc Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus
EP1948633B1 (en) 2005-10-11 2011-08-10 Centre National De La Recherche Scientifique (Cnrs) 3 -hydroxyflavone derivatives for the detection and the quantification of cell apoptosis
ATE517874T1 (de) 2005-10-21 2011-08-15 Exelixis Inc Pyrimidinone als modulatoren von caseinkinase ii (ck2)
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
WO2007070504A2 (en) 2005-12-13 2007-06-21 Morton Grove Pharmaceuticals, Inc. Stable and palatable oral liquid sumatriptan compositions
US20080108611A1 (en) 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
WO2010093928A2 (en) 2009-02-12 2010-08-19 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
KR100846988B1 (ko) 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
MX2008011220A (es) 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
GB0606805D0 (en) 2006-04-04 2006-05-17 Novartis Ag Organic compounds
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
EP1873157A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TW201345908A (zh) 2006-07-05 2013-11-16 Mitsubishi Tanabe Pharma Corp 吡唑并〔１，５-ａ〕嘧啶化合物
EP2058309A4 (en) * 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
BRPI0714665A2 (pt) 2006-08-04 2012-03-13 Takeda Pharmaceutical Company Limited Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP2010502716A (ja) 2006-09-07 2010-01-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド インターロイキン１受容体関連キナーゼの調節物質
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
US7750007B2 (en) 2006-11-06 2010-07-06 Supergen, Inc. Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors
US7820684B2 (en) 2007-03-01 2010-10-26 Supergen, Inc. Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
CA2682016A1 (en) * 2007-03-28 2008-10-02 Inovacia Ab Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase
JP5374492B2 (ja) 2007-04-03 2013-12-25 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害薬としてのイミダゾ［１，２−ａ］ピリジン化合物
JP5160637B2 (ja) 2007-05-04 2013-03-13 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−ｋｉｔおよびＰＤＧＦＲキナーゼインヒビターとしての化合物および組成物
ES2435454T3 (es) 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-onas y aza-indolin-2-onas
SG183049A1 (en) 2007-07-20 2012-08-30 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
HRP20141025T1 (hr) 2007-08-10 2015-01-02 Regeneron Pharmaceuticals, Inc. Humana antitijela s visokim afinitetom za humani faktor rasta živaca
JP2011500702A (ja) 2007-10-16 2011-01-06 ワイス・エルエルシー チエノピリミジンおよびピラゾロピリミジン化合物ならびにｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのその使用
KR20100089851A (ko) 2007-10-23 2010-08-12 노파르티스 아게 호흡기 질환의 치료를 위한 ｔｒｋｂ 항체의 용도
EP2217601A1 (en) 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
CA2706946A1 (en) 2007-11-28 2009-06-04 Schering Corporation 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101290503B1 (ko) 2008-01-17 2013-07-26 아이알엠 엘엘씨 개선된 항-ｔｒｋｂ 항체
EP2273975B8 (en) 2008-03-03 2014-12-17 UCB Pharma, S.A. Pharmaceutical solutions, process of preparation and therapeutic uses
KR100963051B1 (ko) 2008-03-14 2010-06-09 광동제약 주식회사 입자크기가 조절된 술포데히드로아비에트산을 함유한쓴맛이 저감된 경구용 액상 조성물
US20090275622A1 (en) 2008-04-30 2009-11-05 Prasoona Linga Nizatidine formulations
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
WO2010012733A1 (en) 2008-07-29 2010-02-04 Nerviano Medical Sciences S.R.L. Use of a cdk inhibitor for the treatment of glioma
ES2464461T3 (es) 2008-09-22 2014-06-02 Array Biopharma, Inc. Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa
SG196855A1 (en) 2008-10-22 2014-02-13 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
JP5769199B2 (ja) 2008-10-31 2015-08-26 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｊａｋ阻害剤化合物と方法
WO2010058006A1 (en) 2008-11-24 2010-05-27 Nerviano Medical Sciences S.R.L. Cdk inhibitor for the treatment of mesothelioma
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CN102821607B (zh) 2009-12-21 2014-12-17 萨穆梅德有限公司 1H-吡唑并[3，4-b]吡啶及其治疗应用
US9161944B2 (en) 2010-02-18 2015-10-20 Inserm (Institut National De La Sante Et De La Sante Et De La Recherche Medicale) Method for preventing cancer metastasis
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
US8543395B2 (en) 2010-05-18 2013-09-24 Shazam Entertainment Ltd. Methods and systems for performing synchronization of audio with corresponding textual transcriptions and determining confidence values of the synchronization
AU2011256380C1 (en) 2010-05-20 2016-09-08 Array Biopharma Inc. Macrocyclic compounds as Trk kinase inhibitors
EP3889254B8 (en) 2010-06-09 2024-10-02 Dana-Farber Cancer Institute, Inc. A mek1 mutation conferring resistance to raf and mek inhibitors
ES2910305T3 (es) 2010-08-19 2022-05-12 Zoetis Belgium S A Anticuerpos anti-NGF y su uso
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
SG192795A1 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as trk inhibitors
HRP20161786T1 (hr) 2011-05-13 2017-03-10 Array Biopharma, Inc. Pirolidinil urea, pirolidinil tiourea i pirolidinil gvanidin spojevi kao inhibitori trka kinaze
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
HK1202377A1 (en) 2011-11-14 2015-10-02 Tesaro Inc. Modulating certain tyrosine kinases
CA2858958C (en) 2011-12-12 2016-10-04 Dr. Reddy's Laboratories Ltd. Substituted pyrazolo[1,5-a]pyridine as tropomyosin receptor kinase (trk) inhibitors
ES2605388T3 (es) 2012-04-26 2017-03-14 Ono Pharmaceutical Co., Ltd. Compuesto inhibidor de Trk
PL3290414T3 (pl) 2012-05-23 2020-01-31 Nerviano Medical Sciences S.R.L. Sposób otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]-4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran-4-yloamino)benzamidu
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
AU2013282402A1 (en) 2012-06-28 2015-01-22 Mcneil-Ppc, Inc. Racecadotril liquid compositions
US10954567B2 (en) 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
EP2689778A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
CA2882759C (en) 2012-08-31 2018-11-20 The Regents Of The University Of Colorado Detection of the ntrk1-mprip gene fusion for cancer diagnosis
US20140084039A1 (en) 2012-09-24 2014-03-27 Electro Scientific Industries, Inc. Method and apparatus for separating workpieces
JP2014082984A (ja) 2012-10-23 2014-05-12 Astellas Pharma Inc 新規ｎｔｒｋ２活性化変異の検出法
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
UA117573C2 (uk) 2012-11-13 2018-08-27 Ерей Біофарма Інк. Біциклічні сполуки сечовини, тіосечовини, гуанідину й ціаногуанідину, придатні для лікування болю
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
UA116455C2 (uk) 2012-11-13 2018-03-26 Еррей Біофарма Інк. Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka
EP2925359A2 (en) 2012-11-29 2015-10-07 Yeda Research and Development Co., Ltd. Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
CA2901332A1 (en) 2013-02-19 2014-08-28 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
EP2981613A4 (en) 2013-02-22 2016-11-02 Boris C Bastian FUSION POLYNUCLEOTIDES AND FUSION POLYPEPTIDES ASSOCIATED WITH CANCER, IN PARTICULAR MELANOMA, AND THEIR USES AS THERAPEUTIC AND DIAGNOSTIC TARGETS
US20140243332A1 (en) 2013-02-27 2014-08-28 Oregon Health & Science University Methods of treating cancers characterized by aberrent ros1 activity
WO2014152777A2 (en) 2013-03-15 2014-09-25 Insight Genetics, Inc. Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors
ES2900301T3 (es) 2013-03-15 2022-03-16 Novartis Ag Biomarcadores asociados con la inhibición de BRM
KR20150129847A (ko) 2013-03-15 2015-11-20 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 융합 단백질 및 이들의 방법
EP3795696B1 (en) 2013-03-15 2023-04-26 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
JP2016518123A (ja) 2013-04-17 2016-06-23 ライフ テクノロジーズ コーポレーション 癌に関連付けられる遺伝子融合物及び遺伝子変異型
RU2656591C2 (ru) 2013-07-11 2018-06-06 Бетта Фармасьютикалз Ко., Лтд Модуляторы протеин-тирозинкиназы и способы их применения
US10705087B2 (en) 2013-07-26 2020-07-07 Japanese Foundation For Cancer Research Detection method for NTRK3 fusion
EP3628749A1 (en) 2013-07-30 2020-04-01 Blueprint Medicines Corporation Ntrk2 fusions
MX2016004678A (es) 2013-10-24 2017-03-10 Univ Georgetown Composiciones para el tratamiento del cancer.
WO2015064621A1 (ja) 2013-10-29 2015-05-07 公益財団法人がん研究会 新規融合体及びその検出法
PL3097107T3 (pl) 2014-01-24 2020-01-31 Turning Point Therapeutics, Inc. Diarylowe związki makrocykliczne jako modulatory kinaz białkowych
HUE055357T2 (hu) 2014-02-05 2021-11-29 VM Oncology LLC Vegyületek kompozíciói és azok alkalmazásai
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CN109970614B (zh) 2014-05-15 2023-01-13 阵列生物制药公司 作为trka激酶抑制剂的化合物及其用途
WO2015183837A1 (en) 2014-05-27 2015-12-03 Brian Haynes Compositions, methods, and uses related to ntrk2-tert fusions
US20170114415A1 (en) 2014-05-30 2017-04-27 The Regents Of The University Of Colorado, A Body Corporate Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
MX2017001302A (es) 2014-08-01 2017-10-11 Pharmacyclics Llc Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk.
TWI560185B (en) 2014-08-18 2016-12-01 Ono Pharmaceutical Co Acid addition salt of trk inhibitor compound
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
EP3699181B1 (en) 2014-11-16 2023-03-01 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
EP4420732A3 (en) 2014-12-15 2024-11-27 CMG Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors
CN104672121B (zh) 2015-02-16 2017-10-24 上海华默西医药科技有限公司 2r‑(2,5‑二氟苯基)吡咯烷盐酸盐的制备方法
IL302102A (en) 2015-05-20 2023-06-01 Dana Farber Cancer Inst Inc shared neoantigens
CN107849113B (zh) 2015-05-29 2022-03-22 亚尼塔公司 用于治疗具有rtk突变细胞的患者的组合物和方法
AU2016270803A1 (en) 2015-06-01 2018-01-04 Loxo Oncology, Inc. Methods of diagnosing and treating cancer
US9782400B2 (en) 2015-06-19 2017-10-10 Macau University Of Science And Technology Oncogenic ROS1 and ALK kinase inhibitor
AU2015101722A4 (en) 2015-06-19 2016-05-19 Macau University Of Science And Technology Oncogenic ros1 and alk kinase inhibitor
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
US10724102B2 (en) 2015-10-26 2020-07-28 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
WO2017127835A2 (en) 2016-01-22 2017-07-27 The Medicines Company Aqueous formulations and methods of preparation and use thereof
JPWO2017155018A1 (ja) 2016-03-11 2019-01-17 小野薬品工業株式会社 Ｔｒｋ阻害剤抵抗性の癌治療剤
PL3439663T3 (pl) 2016-04-04 2024-11-18 Loxo Oncology, Inc. Sposoby leczenia nowotworów wieku dziecięcego
SG11201808559PA (en) 2016-04-04 2018-10-30 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RU2757905C2 (ru) 2016-04-19 2021-10-22 Экселиксис, Инк. Способ лечения трижды негативного рака молочной железы
WO2017201156A1 (en) 2016-05-18 2017-11-23 Duke University Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab
FI3800189T3 (fi) 2016-05-18 2023-07-31 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin valmistaminen
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers

Also Published As

Publication number Publication date
ME03010B (me) 2018-10-20
HRP20180746T1 (hr) 2018-06-29
PT3372605T (pt) 2021-12-09
MY169791A (en) 2019-05-15
US11267818B2 (en) 2022-03-08
IL247884B (en) 2020-10-29
IL247884A0 (en) 2016-11-30
KR101634833B1 (ko) 2016-06-29
US9447104B2 (en) 2016-09-20
JP5832597B2 (ja) 2015-12-16
SG10201914059WA (en) 2020-03-30
CN103509017A (zh) 2014-01-15
DK3106463T3 (en) 2018-06-06
PT3106463T (pt) 2018-05-18
US8865698B2 (en) 2014-10-21
HUE037716T2 (hu) 2018-09-28
PL2350071T3 (pl) 2014-06-30
TR201807039T4 (tr) 2018-06-21
SI3372605T1 (sl) 2022-03-31
LT2725028T (lt) 2016-09-26
JP2019034961A (ja) 2019-03-07
AU2009308465B2 (en) 2015-02-12
ES2669581T3 (es) 2018-05-28
BRPI0919873B1 (pt) 2020-04-14
PL3106463T6 (pl) 2020-07-27
RU2011120345A (ru) 2012-11-27
MX2011004204A (es) 2011-08-12
HK1160640A1 (en) 2012-08-10
US10047097B2 (en) 2018-08-14
EP2350071B1 (en) 2014-01-08
US20110195948A1 (en) 2011-08-11
RU2018131134A (ru) 2020-03-02
KR102037619B1 (ko) 2019-10-28
SI3106463T1 (en) 2018-08-31
SG10201900514RA (en) 2019-02-27
LTPA2020504I1 (lt) 2020-03-25
JP6105008B2 (ja) 2017-03-29
US20150005499A1 (en) 2015-01-01
US20150133429A1 (en) 2015-05-14
KR20110074617A (ko) 2011-06-30
RU2018131134A3 (enExample) 2021-12-23
JP2016210816A (ja) 2016-12-15
US9127013B2 (en) 2015-09-08
US10774085B2 (en) 2020-09-15
CN102264736B (zh) 2013-08-14
TW201500361A (zh) 2015-01-01
JP2014177494A (ja) 2014-09-25
CY1124923T1 (el) 2023-01-05
IL212341A0 (en) 2011-06-30
KR20170116220A (ko) 2017-10-18
CR20110261A (es) 2011-06-09
PT2350071E (pt) 2014-04-11
LUC00150I2 (enExample) 2021-02-15
EP2725028A1 (en) 2014-04-30
JP5600111B2 (ja) 2014-10-01
TW201020253A (en) 2010-06-01
NO2020004I1 (no) 2020-03-10
PL3372605T3 (pl) 2022-03-07
TW201731848A (zh) 2017-09-16
EP3106463B1 (en) 2018-02-28
RS57221B2 (sr) 2020-08-31
RS53247B (sr) 2014-08-29
CN102264736A (zh) 2011-11-30
ES2456346T3 (es) 2014-04-22
US20230234955A1 (en) 2023-07-27
DK3106463T6 (da) 2020-02-24
IL278119B (en) 2022-06-01
TWI639605B (zh) 2018-11-01
AR112833A2 (es) 2019-12-18
CA2741313C (en) 2018-12-04
US20170114067A1 (en) 2017-04-27
PL3106463T3 (pl) 2018-08-31
NO3106463T3 (enExample) 2018-07-28
KR101652189B1 (ko) 2016-08-29
TW201835086A (zh) 2018-10-01
BRPI0919873B8 (pt) 2021-05-25
SI2350071T1 (sl) 2014-05-30
AU2009308465A1 (en) 2010-04-29
ES2900243T3 (es) 2022-03-16
UA106054C2 (uk) 2014-07-25
US20210002287A1 (en) 2021-01-07
US10005783B2 (en) 2018-06-26
HUE030413T2 (en) 2017-05-29
LTC3106463I2 (lt) 2021-06-25
TWI458729B (zh) 2014-11-01
HUS000512I2 (hu) 2021-03-29
KR101853026B1 (ko) 2018-04-27
CN103509017B (zh) 2015-10-07
LT3106463T (lt) 2018-06-25
KR20140129384A (ko) 2014-11-06
HK1193101A1 (zh) 2014-09-12
CA2741313A1 (en) 2010-04-29
CO6440551A2 (es) 2012-05-15
HRP20180746T4 (hr) 2020-02-21
SMT201800244T1 (it) 2018-07-17
SMT201400153B (it) 2015-01-15
ES2669581T7 (es) 2020-07-29
EP3372605B1 (en) 2021-11-03
HUS2000006I1 (hu) 2020-04-28
JP6788649B2 (ja) 2020-11-25
SG196855A1 (en) 2014-02-13
EP2725028B1 (en) 2016-05-25
IL278119A (en) 2020-11-30
KR101784798B1 (ko) 2017-10-16
KR20160104085A (ko) 2016-09-02
CY1118199T1 (el) 2017-06-28
PL2725028T3 (pl) 2016-12-30
HRP20211722T1 (hr) 2022-02-04
LT3372605T (lt) 2022-02-10
RS57221B1 (sr) 2018-07-31
CY2020006I1 (el) 2020-05-29
TWI670272B (zh) 2019-09-01
RU2523544C2 (ru) 2014-07-20
CY2020006I2 (el) 2020-11-25
RS62869B1 (sr) 2022-02-28
JP2012506446A (ja) 2012-03-15
EP3106463B3 (en) 2020-01-22
HUE057625T2 (hu) 2022-05-28
DK3372605T3 (da) 2021-11-22
DK2350071T3 (en) 2014-03-24
US8513263B2 (en) 2013-08-20
JP2015214590A (ja) 2015-12-03
US20190211017A1 (en) 2019-07-11
UY32192A (es) 2011-05-31
US20180127427A1 (en) 2018-05-10
US20240132500A1 (en) 2024-04-25
WO2010048314A1 (en) 2010-04-29
HRP20140309T1 (hr) 2014-05-09
EP3372605A1 (en) 2018-09-12
TWI577680B (zh) 2017-04-11
RU2014120150A (ru) 2015-11-27
DK2725028T3 (en) 2016-09-05
AR074052A1 (es) 2010-12-22
EP3106463A1 (en) 2016-12-21
JP6431512B2 (ja) 2018-11-28
NZ592809A (en) 2012-09-28
CL2011000880A1 (es) 2011-07-08
NL301033I2 (nl) 2020-04-15
LUC00150I1 (enExample) 2020-03-13
US20140194403A1 (en) 2014-07-10
EP2350071A1 (en) 2011-08-03
KR20180043851A (ko) 2018-04-30
US20160228441A1 (en) 2016-08-11
BRPI0919873A2 (pt) 2019-02-05
CY1120260T1 (el) 2019-07-10
ES2588504T3 (es) 2016-11-03
US9676783B2 (en) 2017-06-13
SI2725028T1 (sl) 2016-10-28
RU2666367C2 (ru) 2018-09-07

Similar Documents

Publication Publication Date Title
HUS2000006I1 (hu) Szubsztituált pirazolo[1,5-a]pirimidin vegyületek mint TRK kináz inhibitorok
HUS2400038I1 (hu) Pirrolo[2,3-d]primidin származékok, mint protein kináz B inhibitorok
ZA201200982B (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
PL2350075T3 (pl) Podstawione związki imidazo[1,2b]pirydazynowe jako inhibitory kinaz Trk
IL201300A0 (en) Imidazo [1, 2 - a] pyridine compounds as receptor tyrosine kinase inhibitors
ZA201004368B (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
EP1713793A4 (en) PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS